Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal...
New artificial intelligence algorithm flags and triages suspected abdominal aortic aneurysms SAN FRANCISCO – March 21, 2023- Viz.ai, the leader...
Mar 21, 2023
All Resources
Explore our latest resources
Viz.ai Named One of Fierce Medtech’s “Fierce 15” Companies of 2022
Annual list recognizes innovative medtech companies that are advancing the art and science of healthcare SAN FRANCISCO – March 20,...
Mar 20, 2023
Key Takeaways from the SIR 2023 Annual Scientific Meeting
This year, Viz.ai had the pleasure of attending and connecting with interventional and diagnostic radiologists from all across the world...
Mar 13, 2023
Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial
Viz.ai’s AI-powered clinical research platform will be used to find, screen and enroll patients in a landmark study of catheter-directed...
Mar 04, 2023
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management...
Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and...
Mar 02, 2023
New Requirements Establishing AI as Standard of Stroke Care
We fully support today’s AHA requirements at ISC establishing AI as standard of care for stroke All levels of stroke...
Feb 28, 2023
February 22, 2023
February 16, 2023
Top 3 Takeaways From ISC 2023
The Viz.ai team just returned from attending the International Stroke Conference (ISC), a 3-day conference where thousands of attendees collaborate...
Feb 16, 2023